All In Biotech

NDA 022360 · Haleon US Holdings

Nicorette

Nicotine Polacrilex · Oral · Cholinergic Nicotinic Agonist

Last checked: Nov 19, 2026Latest source record: Mar 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

May 18, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

873

97 Phase 3, 66 recruiting

FAERS reports

19,243

3,825 serious, 148 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 31, 2025.

Use • reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • NICORETTE · NICOTINE POLACRILEX EQ 2MG BASE · TROCHE/LOZENGE, ORAL · Over-the-counter
  • NICORETTE · NICOTINE POLACRILEX EQ 4MG BASE · TROCHE/LOZENGE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Nicotine Polacrilex" as an intervention, any sponsor and status, largest first.

All 873 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,355
  • nicotine dependence3,000
  • intentional drug misuse2,815
  • nausea1,649
  • drug administration error1,007
  • malaise856
  • oral discomfort630
  • wrong technique in product usage process620
  • dizziness590
  • dyspepsia573
  • macular degeneration568
  • headache550

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004113
2005188
2006726
20071,058
2008881
2009940
2010947
20111,180
20121,319
20131,064
2014218
20151,302
20161,236
20171,252
20181,068
2019942
2020883
20211,028
2022776
2023656
2024508
2025613
2026345

Recalls

2 FDA enforcement reports for this application.

  • Feb 20, 2014 · Class III · Terminated

    Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.

  • Feb 20, 2014 · Class III · Terminated

    Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 77 on PubMed

Sponsor: Haleon US Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.